Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

215 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses.
Avigan D, Vasir B, Gong J, Borges V, Wu Z, Uhl L, Atkins M, Mier J, McDermott D, Smith T, Giallambardo N, Stone C, Schadt K, Dolgoff J, Tetreault JC, Villarroel M, Kufe D. Avigan D, et al. Among authors: mier j. Clin Cancer Res. 2004 Jul 15;10(14):4699-708. doi: 10.1158/1078-0432.CCR-04-0347. Clin Cancer Res. 2004. PMID: 15269142 Clinical Trial.
The high-dose aldesleukin "select" trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma.
McDermott DF, Cheng SC, Signoretti S, Margolin KA, Clark JI, Sosman JA, Dutcher JP, Logan TF, Curti BD, Ernstoff MS, Appleman L, Wong MK, Khushalani NI, Oleksowicz L, Vaishampayan UN, Mier JW, Panka DJ, Bhatt RS, Bailey AS, Leibovich BC, Kwon ED, Kabbinavar FF, Belldegrun AS, Figlin RA, Pantuck AJ, Regan MM, Atkins MB. McDermott DF, et al. Among authors: mier jw. Clin Cancer Res. 2015 Feb 1;21(3):561-8. doi: 10.1158/1078-0432.CCR-14-1520. Epub 2014 Nov 25. Clin Cancer Res. 2015. PMID: 25424850 Free PMC article. Clinical Trial.
FCGR Polymorphisms Influence Response to IL2 in Metastatic Renal Cell Carcinoma.
Erbe AK, Wang W, Goldberg J, Gallenberger M, Kim K, Carmichael L, Hess D, Mendonca EA, Song Y, Hank JA, Cheng SC, Signoretti S, Atkins M, Carlson A, Mier JW, Panka DJ, McDermott DF, Sondel PM. Erbe AK, et al. Among authors: mier jw. Clin Cancer Res. 2017 May 1;23(9):2159-2168. doi: 10.1158/1078-0432.CCR-16-1874. Epub 2016 Oct 14. Clin Cancer Res. 2017. PMID: 27742794 Free PMC article. Clinical Trial.
Killer immunoglobulin-like receptor (KIR) and KIR-ligand genotype do not correlate with clinical outcome of renal cell carcinoma patients receiving high-dose IL2.
Wang W, Erbe AK, Gallenberger M, Kim K, Carmichael L, Hess D, Mendonca EA, Song Y, Hank JA, Cheng SC, Signoretti S, Atkins M, Carlson A, Weiss JM, Mier J, Panka D, McDermott DF, Sondel PM. Wang W, et al. Among authors: mier j. Cancer Immunol Immunother. 2016 Dec;65(12):1523-1532. doi: 10.1007/s00262-016-1904-8. Epub 2016 Sep 30. Cancer Immunol Immunother. 2016. PMID: 27695964 Free PMC article.
Anti-S1P Antibody as a Novel Therapeutic Strategy for VEGFR TKI-Resistant Renal Cancer.
Zhang L, Wang X, Bullock AJ, Callea M, Shah H, Song J, Moreno K, Visentin B, Deutschman D, Alsop DC, Atkins MB, Mier JW, Signoretti S, Bhasin M, Sabbadini RA, Bhatt RS. Zhang L, et al. Among authors: mier jw. Clin Cancer Res. 2015 Apr 15;21(8):1925-1934. doi: 10.1158/1078-0432.CCR-14-2031. Epub 2015 Jan 14. Clin Cancer Res. 2015. PMID: 25589614 Free PMC article.
215 results